Title
Author
DOI
Article Type
Special Issue
Volume
Issue
CELSR1 enhances doxorubicin resistance by activating the WNT/PCP signaling pathway in breast cancer cells
1Department of Head and neck surgery, Affiliated Cancer Hospital of Xinjiang Medical University, 830011 Urumqi, Xinjiang Uygur Autonomous Region, China
2The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Affiliated Cancer Hospital of Xinjiang Medical University, 830011 Urumqi, Xinjiang Uygur Autonomous Region, China
DOI: 10.22514/ejgo.2024.096 Vol.45,Issue 5,October 2024 pp.91-98
Submitted: 22 January 2024 Accepted: 22 February 2024
Published: 15 October 2024
*Corresponding Author(s): Hongtao Li E-mail: lht4656@163.com
Doxorubicin (Dox) is a widely used chemotherapy drug to inhibit the growth and survival of human breast cancer (BC) cells. Presently, there is a pressing need for the development of new therapeutic strategies to enhance Dox efficacy by overcoming the resistance exhibited by breast cancer cells. Cadherin EGF LAG seven-pass G-type receptor 1 (CELSR1), belonging to the Flamingo subfamily, has been implicated in the progression of various tumors. However, the specific role and mechanisms of CELSR1 in the resistance of breast cancer to drug treatments have yet to be fully understood. This study aims to clarify the role of CELSR1 in conferring resistance to doxorubicin in breast cancer. Our findings demonstrate that CELSR1 expression is elevated in breast cancer tissues. Silencing of CELSR1 significantly reduced the proliferation and motility of breast cancer cells. Moreover, the ablation of CELSR1 decreased the resistance of breast cancer cells to doxorubicin treatment. At the molecular level, CELSR1 was found to activate the Wnt/Planar Cell Polarity (WNT/PCP) signaling pathway in breast cancer cells. In conclusion, CELSR1 plays a crucial role in promoting the migration of breast cancer cells and in enhancing their resistance to doxorubicin through the activation of the WNT/PCP pathway.
Breast cancer (BC); Cancer multidrug resistance; Doxorubicin (Dox); CELSR1; WNT/PCP pathway
Lin Luo,Binlin Ma,Meihui Shan,Alibiyati Aini,Hongtao Li. CELSR1 enhances doxorubicin resistance by activating the WNT/PCP signaling pathway in breast cancer cells. European Journal of Gynaecological Oncology. 2024. 45(5);91-98.
[1] Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993–2015: population based observational cohort study. The BMJ. 2023; 382: p1744.
[2] Ghezelayagh TS, Wu ES, Barber EL, Dao MD, Zsiros E, Urban RR, et al. Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. European Journal of Gynaecological Oncology. 2023; 44: 17–25.
[3] Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annual Review of Pathology: Mechanisms of Disease. 2022; 17: 181–204.
[4] Haffez H, Osman S, Ebrahim HY, Hassan ZA. Growth inhibition and apoptotic effect of pine extract and abietic acid on MCF-7 breast cancer cells via alteration of multiple gene expressions using in vitro approach. Molecules. 2022; 27: 293.
[5] Wohlfromm F, Seyrek K, Ivanisenko N, Troitskaya O, Kulms D, Richter V, et al. RL2 enhances the elimination of breast cancer cells by doxorubicin. Cells. 2023; 12: 2779.
[6] Mody H, Vaidya TR, Lezeau J, Taha K, Ait-Oudhia S. In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach. Frontiers in Pharmacology. 2023; 14: 1239141.
[7] Maltese PE, Michelini S, Ricci M, Maitz S, Fiorentino A, Serrani R, et al. Increasing evidence of hereditary lymphedema caused by CELSR1 loss-of-function variants. American Journal of Medical Genetics Part A. 2019; 179: 1718–1724.
[8] Basta LP, Sil P, Jones RA, Little KA, Hayward-Lara G, Devenport D. Celsr1 and Celsr2 exhibit distinct adhesive interactions and contributions to planar cell polarity. Frontiers in Cell and Developmental Biology. 2022; 10: 1064907.
[9] Wei S, Qi L, Wang L. Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis. Anti-Cancer Drugs. 2021; 32: 496–507.
[10] Alpaslan M, Mestre-Godin S, Lay A, Giacalone G, Helaers R, Adham S, et al. Ureteropelvic junction obstruction with primary lymphoedema associated with CELSR1 variants. Journal of Medical Genetics. 2023; 60: 1161–1168.
[11] Wang G, Li Y, Zhang D, Zhao S, Zhang Q, Luo C, et al. CELSR1 acts as an oncogene regulated by miR-199a-5p in glioma. Cancer Management and Research. 2020; 12: 8857–8865.
[12] Hummel D, Becks A, Men H, Bryda EC, Glasco DM, Chandrasekhar A. Celsr1 suppresses Wnt5a-mediated chemoattraction to prevent incorrect rostral migration of facial branchiomotor neurons. Development. 2022; 149: dev200553.
[13] Bui DLH, Roach A, Li J, Bandekar SJ, Orput E, Raghavan R, et al. The adhesion GPCRs CELSR1–3 and LPHN3 engage G proteins via distinct activation mechanisms. Cell Reports. 2023; 42: 112552.
[14] Zuo J, Zheng A, Wang X, Luo Z, Chen Y, Cheng X, et al. Upregulation of CELSR1 expression promotes ovarian cancer cell proliferation, migration, and invasion. Medical Oncology. 2023; 41: 10.
[15] Stahley SN, Basta LP, Sharan R, Devenport D. Celsr1 adhesive interactions mediate the asymmetric organization of planar polarity complexes. eLife. 2021; 10: e62097.
[16] Usami FM, Arata M, Shi D, Oka S, Higuchi Y, Tissir F, et al. Intercellular and intracellular cilia orientation is coordinated by CELSR1 and CAMSAP3 in oviduct multi-ciliated cells. Journal of Cell Science. 2021; 134: jcs257006.
[17] Rogers S, Zhang C, Anagnostidis V, Liddle C, Fishel ML, Gielen F, et al. Cancer-associated fibroblasts influence Wnt/PCP signaling in gastric cancer cells by cytoneme-based dissemination of ROR2. Proceedings of the National Academy of Sciences. 2023; 120: e2217612120.
[18] Luga V, Zhang L, Viloria-Petit A, Ogunjimi A, Inanlou M, Chiu E, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151: 1542–1556.
[19] Hu Y, Liu J, Lu J, Wang P, Chen J, Guo Y, et al. SFRP1 protects H9c2 cardiac myoblasts from doxorubicin-induced apoptosis by inhibiting the Wnt/PCP-JNK pathway. Acta Pharmacologica Sinica. 2020; 41: 1150–1157.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top